Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Four RNAi-Related Patent Applications: Feb 9, 2006

Premium

Title: Immunostimulatory siRNA Molecules and Uses Thereof

Number: 20060025366

Filed: June 30, 2005

Lead Inventor: Ian MacLachlan, Protiva Biotherapeutics

The invention "provides siRNA molecules and methods of using such siRNA molecules to modulate an immune response and to silence expression of a target gene," the patent application's abstract states.


Title: RNA Interference-Mediated Inhibition of Protein Tyrosine Phosphate-1B Gene Expression Using Short Interfering Nucleic Acid

Number: 20060025361

Filed: Jan. 14, 2005

Lead Inventor: James McSwiggen, Sirna Therapeutics

The invention, the patent application's abstract states, "relates to compounds, compositions, and methods useful for modulating protein tyrosine phosphatase-1B gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of PTP-1B gene expression and/or activity by RNA interference using small nucleic acid molecules. … Such small nucleic acid molecules are useful, for example, for treating, preventing, inhibiting, or reducing obesity, insulin resistance, diabetes in a subject or organism, and for any other disease, trait, or condition that is related to or will respond to the levels of PTP-1B in a cell or tissue, alone or in combination with other treatments or therapies."


Title: RNA Interference Pathway Genes as Tools for Targeted Genetic Interference

Number: 20060024798

Filed: June 3, 2005

Lead Inventor: Craig Mello, University of Massachusetts

"Genes involved in double-stranded RNA interference are identified and used to investigate the RNAi pathway," the patent application's abstract states. "The genes and their products are also useful for modulating RNAi pathway activity."


Title: Methods and Products Related to the Production of Inner Ear Hair Cells

Number: 20060024278

Filed: Jan. 24, 2005

Inventor: Zheng-Yi Chen, Massachusetts General Hospital (Sirna Therapeutics)

"The invention relates to the generation of inner ear sensory epithelial cells through the manipulation of the expression level or function of the genes and/or proteins involved in the retinoblastoma (Rb) pathway, particularly retinoblastoma family members, such as Rb1," the patent application's abstract states. "Methods for generating inner ear sensory epithelial cells and for restoring hearing or balance in a subject, therefore, are provided. The invention further relates to cell lines of inner ear sensory epithelial cells, such as progenitor, supporting or hair cells, where the expression level or function of the retinoblastoma genes and/or retinoblastoma proteins has been manipulated" with the use of an RNAi or siRNA molecule. "In addition to these methods, compositions of agents for use in or the cells produced by such methods provided are also included," the abstract adds. "Finally, the invention also relates to methods and compositions for the generation of inner ear sensory epithelial cells through the manipulation of Isl-1 alone or in combination with the manipulation of retinoblastoma gene and/or retinoblastoma protein."

The Scan

Rise of BA.5

The New York Times reports that the Omicron subvariant BA.5 has become the dominant version of SARS-CoV-2 in the US.

UK Health Secretary Resigns

Sajid Javid, the UK health secretary, resigned along with Chancellor Rishi Sunak, saying they cannot work with Prime Minister Boris Johnson's government, CNN reports.

Clones From Freeze-Dried Cells

A team in Japan has cloned mice from freeze-dried skin cells, according to the Guardian.

Genome Research Papers on Craniosynostosis, Macaque Retrotransposition, More

In Genome Research this week: structural variants in craniosynostosis, LINE-1 activity in rhesus macaque brain, and more.